NCT07609524

Brief Summary

To collect data, written consent was obtained from the hospital and university administration. After receiving signed informed consent, the data was collected from cardiac patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jun 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 12, 2025

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 19, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

September 20, 2025

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

May 8, 2026

Completed
19 days until next milestone

First Posted

Study publicly available on registry

May 27, 2026

Completed
Last Updated

May 27, 2026

Status Verified

May 1, 2026

Enrollment Period

2 months

First QC Date

May 8, 2026

Last Update Submit

May 19, 2026

Conditions

Outcome Measures

Primary Outcomes (3)

  • Anthropometric Measurements

    for body mass index weight in kg and height in meters squared, were used to calculate changes in body size.

    60 days

  • Lipid Profile

    Blood lipid profile was obtained using fasting blood samples to determine serum total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and triglycerides were monitored pre and post intervention.

    60 days

  • Blood pressure

    Blood pressure was checked using an automated sphygmomanometer. Sitting blood pressure was measured in two ways; systolic blood pressure and diastolic blood pressure after 5 minutes rest. For analysis, the average of the three readings were taken.

    60 days

Study Arms (3)

Control group on whole wheat bread

PLACEBO COMPARATOR

Participants were only subjected to use Wheat bread in breakfast.

Dietary Supplement: Control on Wheat bread

G1 on 40% WRB

EXPERIMENTAL

Participants were advised to take Watermelon rind-based bread (40% ) in breakfast for the duration of 02 months.

Dietary Supplement: Experimental G1 on WRB

G 2 on 60% WRB

EXPERIMENTAL

Participants were advised to take Watermelon rind-based bread (60% ) in breakfast for the duration of 02 month.

Dietary Supplement: Experimental G2 on WRB

Interventions

Control on Wheat breadDIETARY_SUPPLEMENT

Participants were advised to take Two slices of wheat bread in breakfast for the duration of 02 months.

Control group on whole wheat bread
Experimental G1 on WRBDIETARY_SUPPLEMENT

Participants were advised to take 2 slices of Watermelon rind-based bread in breakfast for the duration of 02 months.

G1 on 40% WRB
Experimental G2 on WRBDIETARY_SUPPLEMENT

Group 2: Participants were advised to take 2 slices of Watermelon rind-based bread in breakfast for the duration of 02 months.

G 2 on 60% WRB

Eligibility Criteria

Age35 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may not qualify if:

  • Any person allergic to wheat.
  • Any person any person allergic to watermelon rind.
  • Any adult having pancreatitis and hepatitis.
  • Any adults having serious health conditions like cancer.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Lahore

Lahore, Punjab Province, Pakistan

Location

Related Publications (1)

  • Karimi E, Abaj F, Gholizadeh M, Asbaghi O, Amini MR, Ghaedi E, Hadi A. Watermelon consumption decreases risk factors of cardiovascular diseases: A systematic review and meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2023 Aug;202:110801. doi: 10.1016/j.diabres.2023.110801. Epub 2023 Jun 25.

Study Officials

  • Maria Aslam

    University of Lahore

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Head University Institute of Diet and Nutritional Sciences

Study Record Dates

First Submitted

May 8, 2026

First Posted

May 27, 2026

Study Start

June 12, 2025

Primary Completion

August 19, 2025

Study Completion

September 20, 2025

Last Updated

May 27, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will not share

Locations